Roth Capital Brokers Raise Earnings Estimates for GANX

Key Points

• Roth Capital has raised its Q3 2025 earnings per share (EPS) estimate for Gain Therapeutics to ($0.16), improving from the prior estimate of ($0.18), with a price target of $6.00.
• Gain Therapeutics' last reported EPS was ($0.19), which was below the consensus estimate of ($0.17).
• HC Wainwright maintained a "buy" rating and set a target price of $8.00 for the stock, with a consensus target price of $7.80 across five analysts.

Gain Therapeutics, Inc. (NASDAQ:GANX - Free Report) - Roth Capital boosted their Q3 2025 earnings per share (EPS) estimates for Gain Therapeutics in a research report issued to clients and investors on Tuesday, August 12th. Roth Capital analyst B. Pachaiyappan now expects that the company will post earnings per share of ($0.16) for the quarter, up from their previous forecast of ($0.18). Roth Capital has a "Buy" rating and a $6.00 price target on the stock. The consensus estimate for Gain Therapeutics' current full-year earnings is ($1.00) per share. Roth Capital also issued estimates for Gain Therapeutics' Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.69) EPS, Q1 2026 earnings at ($0.16) EPS, Q2 2026 earnings at ($0.19) EPS, Q3 2026 earnings at ($0.21) EPS, Q4 2026 earnings at ($0.24) EPS and FY2026 earnings at ($0.81) EPS.

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $8.00 price objective on shares of Gain Therapeutics in a research note on Thursday, July 3rd. Five research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $7.80.

Gain Therapeutics Trading Down 0.6%

Gain Therapeutics stock traded down $0.01 during trading on Friday, reaching $1.68. 118,766 shares of the company were exchanged, compared to its average volume of 277,160. Gain Therapeutics has a 52-week low of $0.95 and a 52-week high of $3.19. The company has a market capitalization of $60.39 million, a P/E ratio of -2.67 and a beta of 0.10. The company has a debt-to-equity ratio of 0.09, a current ratio of 1.79 and a quick ratio of 1.79. The stock's 50 day simple moving average is $1.67 and its two-hundred day simple moving average is $1.89.

Gain Therapeutics (NASDAQ:GANX - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.02).

Hedge Funds Weigh In On Gain Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Marshall Wace LLP acquired a new stake in Gain Therapeutics during the 4th quarter worth approximately $198,000. Northern Trust Corp raised its holdings in Gain Therapeutics by 88.2% during the fourth quarter. Northern Trust Corp now owns 84,586 shares of the company's stock worth $183,000 after purchasing an additional 39,642 shares during the last quarter. Bridgeway Capital Management LLC acquired a new position in Gain Therapeutics during the fourth quarter worth $65,000. Dauntless Investment Group LLC acquired a new stake in shares of Gain Therapeutics during the first quarter valued at $240,000. Finally, Kovitz Investment Group Partners LLC acquired a new position in Gain Therapeutics in the 1st quarter valued at about $91,000. 11.97% of the stock is owned by institutional investors and hedge funds.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.